CTBO (Cantabio Pharmaceuticals) YoY EPS Growth: 119.63% (As of Dec. 2018)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cantabio Pharmaceuticals YoY EPS Growth?

Cantabio Pharmaceuticals CTBO YoY EPS Growth is 119.63% as of Dec. 2018.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Cantabio Pharmaceuticals's YoY EPS Growth for the quarter that ended in Dec. 2018 was 119.63%.

Cantabio Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Dec. 2018 was $19.63.

Cantabio Pharmaceuticals YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Cantabio Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cantabio Pharmaceuticals YoY EPS Growth Chart

Cantabio Pharmaceuticals Annual Data
Trend Mar12 Mar13 Mar14 Mar15 Mar16 Mar17 Mar18
YoY EPS Growth
Get a 7-Day Free Trial -100.00 350.00 -500.00 0.00 -75.00

Cantabio Pharmaceuticals Quarterly Data
Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.00 -200.00 0.00 0.00 119.63

Cantabio Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Cantabio Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Mar. 2018 is calculated as:

YoY EPS Growth (A: Mar. 2018 )
=(Earnings per Share (Diluted) (A: Mar. 2018 )-Earnings per Share (Diluted) (A: Mar. 2017 ))/ | Earnings per Share (Diluted) (A: Mar. 2017 ) |
=(-350--200)/ | -200 |
=-75.00 %

Cantabio Pharmaceuticals's YoY EPS Growth for the quarter that ended in Dec. 2018 is calculated as:

YoY EPS Growth (Q: Dec. 2018 )
=(Earnings per Share (Diluted) (Q: Dec. 2018 )-Earnings per Share (Diluted) (Q: Dec. 2017 )) / | Earnings per Share (Diluted) (Q: Dec. 2017 )) |
=(19.628--100)/ | -100 |
=119.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 119.63% mean?
Cantabio Pharmaceuticals (CTBO) has a YoY EPS Growth of 119.63% as of Dec. 2018. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Cantabio Pharmaceuticals and its competitors.
Is Cantabio Pharmaceuticals' YoY EPS Growth too high?
Cantabio Pharmaceuticals' current YoY EPS Growth is 119.63%.
How does Cantabio Pharmaceuticals' YoY EPS Growth compare to TNTY and ETNI?
Cantabio Pharmaceuticals' YoY EPS Growth of 119.63% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Cantabio Pharmaceuticals and its competitors. Cantabio Pharmaceuticals's current YoY EPS Growth is 119.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantabio Pharmaceuticals stock overvalued right now?
Cantabio Pharmaceuticals (CTBO) has a current YoY EPS Growth of 119.63%. The current YoY EPS Growth is 119.63%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Cantabio Pharmaceuticals (CTBO), the current YoY EPS Growth is 119.63% as of Dec. 2018. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cantabio Pharmaceuticals Business Description

Address 1250 Oakmead Parkway, Sunnyvale, CA, USA, 94085
Cantabio Pharmaceuticals Inc is the United States based preclinical stage biotechnology company. It is focused on commercializing novel therapies and the intellectual property generated from its research and development activities for Parkinson's disease and Alzheimer's disease and other related diseases. In addition, In addition, it is also engaged in the development of therapeutic proteins that can pass through the blood-brain barrier and supplement in vivo levels of proteins which display loss of function during disease conditions.